


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 		<b>Application Number</b>	10/534,825
		<b>Filing Date</b>	May 27, 2005
		<b>First Name Inventor</b>	David Thurston
		<b>Group Art Unit</b>	N/A
		<b>Examiner Name</b>	N/A
		<b>Attorney Docket Number</b>	065435-9048 US00
Sheet	1	of	2

**U.S. PATENT DOCUMENTS**

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
BK	3523941	Leimgruber et al	08/11/1970
	3524849	Batcho et al.	08/18/1970
	4185016	Takanabe et al.	01/22/1980
	4239683	Takanabe et al.	12/16/1980
	4309437	Ueda et al.	01/05/1982
	5143854	Pirrung et al.	09/01/1992
	5545568	Ellman et al.	08/13/1996
	6747144	Thurston et al.	06/08/2004
	6562806	Thurston et al.	05/13/2003
	6608192	Thurston et al.	08/19/2003
	2003-0120069	Thurston et al.	06/26/2003
	2003-0195196	Thurston et al.	10/16/2003
	2004-0092736	Thurston et al.	05/13/2004
V	2004-0198722	Thurston et al.	10/07/2004

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
BK	WO	88/07378	Cancer Research Campaign Technology Ltd.	10/06/1988		

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
--------------------	----------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/534,825
				Filing Date	May 27, 2005
				First Name Inventor	David Thurston
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	2	of	2	Attorney Docket Number	065435-9048 US00

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS							
Examiner Initials		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
BK		WO	89/10140	Cancer Research Campaign Technology Ltd.	11/02/1989		
		WO	92/19620	Centre National de la Recherche Scientifique	11/12/1992		
		WO	93/08288	Cancer Research Campaign Technology Ltd.	04/29/1993		
		WO	93/18045	Cancer Research Campaign Technology Ltd.	09/16/1993		
		WO	97/01560	Pharmacoepia, Inc.	01/16/1997		
		WO	00/12506	The University of Portsmouth Higher Education Group	03/09/2000		
		WO	00/12507	The University of Portsmouth Higher Education Corp.	03/09/2000		
		EP	0239400A2	Winter, G.P.	09/30/1987		
		FR	2027356	Fujisawa Pharmaceutical Co. Ltd.	12/29/1969		
		FR	2586683	Centre National de la Recherche Scientifique	03/06/1987		
		GB	1299198	Fujisawa Pharmaceutical Co. Ltd.	12/06/1972		
		JP	53-82792	Microbiological Chemical Research	07/21/1978		
		JP	57131791	Fujisawa Pharmaceutical Co. Ltd.	08/14/1982		
		JP	58180487 A	Kyowa Hakko Kogyo Co. Ltd.	10/21/1983		

Q:\CLIENT\065435\9048\B0620173.1

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
--------------------	----------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

DEC 19 2005

(Use as many sheets as necessary)

Sheet

1

of

3

**Complete if Known**

Application Number	10/534,825
Filing Date	May 27, 2005
First Named Inventor	David Thurston
Group Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	065435-9048 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--

BK	ALBERICIO, F. et al., "NPE-Resin, A New Approach to the Solid-Phase Synthesis of Protected Peptides and Oligonucleotides II. Synthesis of Protected Peptides <sup>1,2</sup> ," <i>Tetrahedron Letters</i> , 32:1515-1518 (1991)
	ALBERICIO, F. et al., "NPE-resin, a new approach to the solid-phase synthesis of protected peptides and oligonucleotides," <i>Peptides</i> 1990, Proc. 21.sub.st Eur. Pept. Symp., 134-136 (1990)
	ALTHIUS, T. H. and HESS, H. J., "Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat," <i>J. Medicinal Chem.</i> , 20(1), 146-148 (1977)
	ARIMA et al., "Studies on Tomaymycin, a New Antibiotic. I. Isolation and Properties of Tomaymycin," <i>J. Antibiotics</i> , 25, 437-444 (1972)
	ARISTOFF, J and JOHNSON, P., "Synthesis of CBI-PDE-I-Dimer, the Benzannelated Analogue of CC-1065," <i>J. Org. Chem.</i> , 57, 6234-6239 (1992)
	BAGSHAWE et al., "Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites," <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 4, 915-922 (1991)
	BARALDI, P.G. et al., "Design, synthesis and biological activity of a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , vol. 8, No. 21, 3019-3024 (1998)
	BARALDI, P.G. et al., "Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers," <i>J. Med. Chem.</i> , 42, 5131-5141 (1999)
	BAYLEY, H. et al., "Photoactivatable drugs," <i>TIPS</i> , 8, 138-143 (1987)
	BERRY, J. M. et al., "Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines," <i>Tetrahedron Letters</i> , 41, 6171-6174 (2000)
	BI, Y. et al., "Building blocks for peptide and carbamate libraries", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , vol. 6, No. 19, 2299-2300 (1996)
	BI, Y., et al., "Building blocks for peptide and carbamate libraries," <i>Chemical Abstracts</i> , vol. 125, No. 23, 1013 (1996)
	BOGER et al., "CC-1065 and the Duocarmycins: Synthetic Studies," <i>Chem. Rev.</i> , 97, 787-828 (1997)
	BOSE et al., "New Approaches to Pyrrolo[2,1-c][1,4]benzodiazepines: Synthesis, DNA-binding and cytotoxicity of DC-81," <i>Tetrahedron</i> , 48, 751-758 (1992)
	BOSE, D.S. et al., "Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System," <i>J. Am. Chem. Soc.</i> , 114, 4939-4941 (1992)
↓	BRIDGES, R.J. et al., "Conformationally Defined Neurotransmitter Analogues. Selective Inhibition of Glutamate Uptake by One Pyrrolidine-2,4-dicarboxylate Diastereomer," <i>J. Med. Chem.</i> , 34, 717-725 (1991)

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/534,825	
			Filing Date	May 27, 2005	
			First Named Inventor	David Thurston	
			Group Art Unit	N/A	
			Examiner Name	N/A	
Sheet	2	of	3	Attorney Docket Number	065435-9048 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--

BK	BROWN, S.C. et al., "NMR Solution Structure of a Peptide Nucleic Acid Complexed with RNA," <i>Science</i> , 265, 777-780 (1994)
	BUNDGAARD, H., "Design and Application of Prodrugs," <i>A Textbook of Drug Design and Development</i> , eds Krogsgaard-Lassen, P., and Bundgaard, H., Harwood Academic Press, 113-135 (1991)
	BURGESS, K. et al., "Solid Phase Synthesis of Oligoureas", <i>J. Am. Chem. Soc.</i> , 119: 1556-1564 (1997)
	BURGESS, K et al., "Solid Phase Synthesis of Unnatural Biopolymers Containing Repeating Urea Units," <i>Agnew Chem. Int. Ed. Engl.</i> 34, No. 8:907-909 (1995)
	CARRUTH, J.A.S., "Clinical applications for photodynamic therapy," <i>J. Photochem Photobiol.</i> , 9, 396-397 (1991)
	CHO, C Y et al., "An Unnatural Biopolymer", <i>Science</i> , 261: 1303-1305 (1993)
	COURTNEY, S. M. et al., "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Tetrahedron Letters</i> , vol. 34, No. 33, 5327-28 (1993)
	CULVER et al., "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," <i>Science</i> , 256, 1550-1552 (1992)
	DALTON, S. and TREISMAN, R., "Characterization of SAP-1, a Protein Recruited by Serum Response Factor to the c-fos Serum Response Element," <i>Cell</i> , 68, 597-612 (1992)
	DAMAYANTHI, Y., et al., "Design and synthesis of novel pyrrolo{2,1-c}[1,4] benzodiazepine-Lexitropsin Conjugates," <i>J. Org. Chem.</i> , 64, 290-292 (1999)
	DANGLES, O. et al., "Selective Cleavage of the Allyl and Allyloxycarbonyl Groups through Palladium-Catalyzed Hydrostannolysis with Tributyltin Hydride. Application to the Selective Protection-Deprotection of Amino Acid Derivatives and in Peptide Synthesis," <i>J. Org. Chem.</i> , 52, 4984-4993 (1987)
	DRESSMAN, B.A., et al., "Solid Phase Synthesis of Hydantoins Using a Carbamate Linker and a Novel Cyclization/Cleavage Step," <i>Tetrahedron Letters</i> , 37, 937-940 (1996)
	DROST, K.J. and CAVA, M.P., "A Photochemically Based Synthesis of the Benzannelated Analogue of the CC-1065 A Unit," <i>J. Org. Chem.</i> , 56:2240-2244 (1991)
	EASHOO, M. et al., "Fibers from a Low Dielectric Constant Fluorinated Polyimide: Solution Spinning and Morphology Control," <i>J. Polymer Science</i> , 35:173-185 (1997)
	EDMAN, P. and BEGG, G., "A Protein Sequenator," <i>Eur. J. Biochem.</i> , 1, 80-91 (1967)
↓	EGHOLM, M et al., "Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone," <i>J. Am. Chem. Soc.</i> , 114, 1895-1897 (1992)

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	May 27, 2005
				First Named Inventor	David Thurston
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	3	of	8	Attorney Docket Number	065435-9048 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--	--

BK		EGHOLM, M et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> , 365, 566-568 (1993)
		ENGLEHARDT et al., "Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses," <i>Nature Genetics</i> , 4, 27-34 (1993)
		FARMER, J.D. et al., "DNA binding properties of a new class of linked anthramycin analogs," <i>Chemical Abstracts</i> , Abstract No. 239940r, vol. 114, No. 25, 25 899-903 (1991)
		FIGLIOZZI, G.M. et al., "Synthesis of N-substituted Glycine Peptoid Libraries," <i>Methods in Enzymology</i> , 267: 437-447 (1996)
		FOLOPPE, M.P. et al., "DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazepine N10-C11 amidines," <i>Eur. J. Med. Chem.</i> , 31, 407-410 (1996)
		FUJISAWA PHARMACEUTICAL CO., LTD., Abstract No. 139983k, "Benzodiazepine derivatives", <i>Chemical Abstracts</i> , vol. 99, No. 17, 603 (1983)
		FUJISAWA PHARMACEUTICAL CO., LTD., Abstract No. 72145x, "Benzodiazepine derivatives", <i>Chemical Abstracts</i> , vol. 98, No. 9, 638 (1983)
		FUJISAWA PHARMACEUTICAL CO. LTD., "Benzodiazepine derivatives," <i>SciFinder Scholar</i> , 2-3 (2002)
		FUKUYAMA, T. et al., "Total Synthesis of (+)-Porothramycin B," <i>Tetrahedron Letters</i> , vol. 34, 16, 2577-2580 (1993)
		FURKA, A. et al., "General method for rapid synthesis of multicomponent peptide mixtures," <i>Int. J. Peptide Protein Res.</i> , 37, 487-493 (1991)
		GARCIA-ECHEVERRIA, C., "A Base Labile Handle for Solid Phase Organic Chemistry", <i>Tetrahedron Letters</i> , 38,52, 8933-8934 (1997)
		GRANT, R. et al., <i>Grant and Hackh's Chemical Dictionary</i> , McGraw-Hill Book Company, 282 (1987)
		GREENE, T.W. and WUTS, P.G.M., <i>Protective Groups in Organic Synthesis</i> , John Wiley & Sons, 2 <sup>nd</sup> ed., Ch 7, 315-345 (1991)
		GREGSON, S. et al., "Synthesis of a novel C2/C2'-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity," <i>Chemical Communications</i> , 797-798 (1999)
		GREGSON, S.J. et al., "Design, Synthesis and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity", <i>J. Med. Chem.</i> , 44: 737-748 (2001)
		GREGSON, S.J. et al., "Effect of C2-exo Unsaturation on the Cytotoxicity and DNA-Binding Reactivity of Pyrrolo[2,1-c]1,4]benzodiazepines", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10: 1845-1847 (2000)

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/534,825	
			Filing Date	May 27, 2005	
			First Named Inventor	David Thurston	
			Group Art Unit	N/A	
			Examiner Name	N/A	
Sheet	4	of	17	Attorney Docket Number	065435-9048 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

BK		GUIOTTO, A. et al., "Synthesis of novel C7-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) via Pro-N10-troc protection and suzuki coupling," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 8, No. 21, 3017-3018 (1998)
		HARA et al., "DC 102, a new glycosidic pyrrolo(1,4)benzodiazepine antibiotic produced by <i>streptomyces</i> sp.," <i>J. Antibiotics</i> , 41, 702-704 (1988)
		HAUSKE, J. R. and DORFF, P., "Solid Phase CBZ Chloride Equivalent. A New Matrix Specific Linker", <i>Tetrahedron Letters</i> , 36, 10, 1589-1592 (1995)
		HOCART et al., "Highly potent cyclic disulfide antagonists of somatostatin," <i>J. of Medicinal Chem.</i> , 42:11 (1999)
		HOCHLOWSKI, J. et al., "Abbeymycin, a new anthramycin-type antibiotic produced by a streptomycete," <i>J. Antibiotics</i> , 40, 145-148 (1987)
		HOLMES, C.P. and JONES, D.G., "Reagents for Combinatorial Organic Synthesis: Development of a New O-Nitrobenzyl Photolabile Linker for Solid Phase Synthesis", <i>J. Org. Chem.</i> , 60, 2318-2319 (1995)
		HUBER, B. et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 88, 8039-8043 (1991)
		HURLEY, L. and NEEDHAM-VANDEVANTER, D., "Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines," <i>Acc. Chem. Res.</i> , 19, 230-237 (1986)
		ITOH et al., "Sibanomicin, a new pyrrolo(1,4)benzodiazepine antitumor antibiotic produced by a <i>micromonospora</i> sp." <i>J. Antibiotics</i> , 41, 1281-1284 (1988)
		JENKINS, T.C. et al., "Structure of a Covalent DNA Minor Groove Adduct with a Pyrrolobenzodiazepine Dimer: Evidence for Sequence-Specific Interstrand Cross-Linking," <i>J. Med. Chem.</i> , 37, 4529-4537 (1994)
		JUNGHEIM, L.N. and SHEPHERD, T.A., "Design of Antitumor Prodrugs: Substrates for Antibody Targeted Enzymes," <i>Am. Chem. Soc. Chem. Rev.</i> , 94, 1553-1566 (1994)
		KAMAL, A., et al., "An Efficient Synthesis of Pyrrolo[2,1-c][1,4] Benzodiazepine Antibiotics via Reductive Cyclization," <i>Bioorg. Med. Chem. Ltrs</i> , 7, No. 14, 1825-1828 (1997)
		KAMAL, A., et al., "Synthesis of Pyrrolo [2,1-c][1,4]-Benzodiazepene Antibiotics: Oxidation of Cyclic Secondary Amine with TPAP", <i>Tetrahedron</i> , v. 53, No. 9, 3223-3230 (1997)
		KAPOOR, T.M. et al., "Exploring the Specificity Pockets of Two Homologous SH3 Domains Using Structure-Based, Split-Pool Synthesis and Affinity-Based Selection," <i>J. Am. Chem. Soc.</i> 120:23-29 (1998)
		KATRITZKY et al., <i>Heterocyclic Chemistry</i> , John Wiley & Sons, Inc., 247-253 (1960)

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
--------------------	----------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	May 27, 2005
				First Named Inventor	David Thurston
				Group Art Unit	N/A
Examiner Name	N/A				
Sheet	5	of	8	Attorney Docket Number	065435-9048 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--

BK		KENNEDY, J.C. and POTTIER, R.H., "Endogenous protoporphyrin IX, a clinical useful photosensitizer for photodynamic therapy," <i>J. Photochem Photobiol</i> , 14, 275-292 (1992)
		KOHN, K., "Anthramycin," <i>Antibiotics III</i> , Springer-Verlag, NY, 3-11 (1975)
		KONISHI, M. et al., "Chicamycin, a new antitumor antibiotic II. Structure determination of chicamycins A and B," <i>J. Antibiotics</i> , 37, 200-206 (1984)
		KUNIMOTO et al., "Mazethramycin, a new member of anthramycin group antibiotics," <i>J. Antibiotics</i> , 33, 665-667 (1980)
		KUNZ, H. and DOMBO, B., "Solid Phase Synthesis of Peptide and Glycopeptides on Polymeric Supports with Allylic Anchor Groups," <i>Angew Chem. Int. Ed. Engl</i> , 5, 711-713 (1988)
		KUZMICH, S. et al., "Increased levels of glutathione S-transferase $\pi$ transcript as a mechanism of resistance to ethacrynic acid," <i>Journal of Biochemistry</i> , 281, 219-224 (1992)
		LANGLEY, D.R. and THURSTON, D.E., "A versatile and efficient synthesis of carbinolamine-containing pyrrolo[1,4]benzodiazepines via the cyclization of N-92-aminobenzoylpyrrolidine-2-carboxaldehyde diethyl thioacetals: total synthesis of prothracarcin," <i>J. Org. Chem.</i> , 52, 91-97 (1987)
		LEBER, J.D. et al., "A revised structure for sibiromycin," <i>J. Am. Chem. Soc.</i> , 110, 2992-2993 (1988)
		LEIMGRUBER, W. et al., "Isolation and characterization of anthramycin, a new antitumor antibiotic," <i>J. Am. Chem. Soc.</i> , 87, 5791-5793 (1965)
		LEIMGRUBER, W. et al., "The structure of anthramycin," <i>J. Am. Chem. Soc.</i> , 87, 5793-5795 (1965)
		LEIMGRUBER, W. et al., "Total synthesis of anthramycin," <i>J. Am. Chem. Soc.</i> , 90, 5641-5643 (1968)
		LESCRINIER, T. et al., "DNA-Binding Ligands from Peptide Libraries Containing Unnatural Amino Acids," <i>Chem. Eur. J.</i> , 4, 3, 425-433 (1998)
		LEWIS A.D. et al., "Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects," <i>Carcinogenesis</i> , 9, 1283-1287 (1988)
		LOWN et al., "Molecular Mechanism of Binding of Pyrrolo(1,4)benzodiazepine antitumour agents to deoxyribonucleic acid - anthramycin and tomaymycin," <i>Biochem. Pharmacol.</i> (1979), 28 (13), 2017-2026; and Abstract No. 51709
✓		MIZUSHIMA, S. and NAGATA, S., "pEF-BOS, a powerful mammalian expression vector," <i>Nucl. Acids Res.</i> , 18, 5322 (1990)

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	May 27, 2005
				First Named Inventor	David Thurston
				Group Art Unit	N/A
Examiner Name	N/A				
Attorney Docket Number	065435-9048 US00				
Sheet	6	of	6		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
-------------------	--

BK		MONKS, A. et al., "Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines," <i>Journal of National Cancer Institute</i> , 83, 757-766 (1991)
		MORAN, E.J. et al., "Novel Biopolymers for Drug Discovery: Biopolymers", <i>Peptide Science</i> , John Wiley and Sons, 37: 213-19 (1995)
		MORGAN, R.A. and ANDERSON, W.F., "Human Gene Therapy," <i>Annu. Rev. Biochem.</i> , 62, 191-217 (1993)
		MOSMANN, T., "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <i>J. Immunological Methods</i> , 65, 55-63 (1983)
		MULLEN, D.G. and BARANY, G., "A New Fluoridolyzable Anchoring Linkage for Orthogonal Solid-Phase Peptide Synthesis: Design, Preparation, and Application of the N-(3 or 4)-[[4-(Hydroxymethyl) phenoxy]-tert-butylphenylsilyl]phenyl Pentanedioic Acid Monoamide (Pbs) Handle", <i>J. Org. Chem.</i> , 53, 5240-5248 (1988)
		NAGASAKA, T. and KOSEKI, Y., "Stereoselective Synthesis of Tilivalline," <i>Journal of Organic Chemistry</i> , vol. 63, No. 20, 6797-6801 (1998)
		NAGASAKA, T. et al., "Stereoselective Synthesis of Tilivalline," <i>Tetrahedron Letters</i> , 30:14, 1871-1872 (1989)
		NICOLAOU, K.C. et al., "Designed Enediynes: A New Class of DNA-Cleaving Molecules with Potent and Selective Anticancer Activity," <i>Science</i> , 256, 1172-1178 (1992)
		NIELSON, P.E. et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide," <i>Science</i> , 254, 1497-1500 (1991)
		O'NEIL, I.A., et al., "The Synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines," <i>Synlett</i> , 75-78 (1997)
		O'NEIL, Chemical Abstract No. 171573p, "The synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines", <i>Chemical Abstracts</i> , vol. 126, No. 13, 618 (1997)
		O'NEIL, I.A. et al., "DPPE: A Convenient Replacement for Triphenylphosphine in the Staudinger and Mitsunobu Reactions", <i>Tetrahedron Letters</i> , vol. 39, No. 42, 7787-7790 (1998)
		PAIKOFF, S.J. et al., "The Solid Phase Synthesis of N-Alkylcarbamate Oligomers", <i>Tetrahedron Letters</i> , 37, No. 32: 5653-5656 (1996)
		PILLAI, V.N.R., "Photoremovable protecting groups in organic chemistry," <i>Synthesis</i> , 1-26 (1980)
V		RAM, Z. et al., "In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats," <i>Cancer Research</i> , 53, 83-88 (1993)

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
--------------------	----------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	May 27, 2005
				First Named Inventor	David Thurston
				Group Art Unit	N/A
Examiner Name	N/A				
Sheet	7	of	8	Attorney Docket Number	065435-9048 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--

BK		RAWAL, V.H. et al., "Photocyclization Strategy for the Synthesis of Antitumor Agent CC-1065: Synthesis of Dideoxy PDE-I and PDE-II. Synthesis of Thiophene and Furan Analogues of Dideoxy PDE-I and PDE-II," <i>J. Org. Chem.</i> , 52, 19-28 (1987)
		REGULA, J. et al., "Photosensitisation and photodynamic therapy of oesophagael, duodenal and colorectal tumours using 5-aminolevulinic acid induced photoporphyrin IX-a pilot study," <i>Gut</i> , 36, 67-75 (1995)
		SAGNOU, M.J. et al., "Design and Synthesis of Novel Pyrrolobenzodiazepine (PDB) Prodrugs for ADEPT and GDEPT," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10, 2083-2086 (2000)
		SAHA, A.K. et al., "Diisopropylsilyl-Linked Oligonucleotide Analogs: Solid-Phase Synthesis and Physicochemical Properties," <i>J. Org. Chem.</i> , 58, 7827-7831 (1993)
		SATYAM, A. et al., "Design, Synthesis, and Evaluation of Latent Alkylating Agents Activated by Glutathione S-Transferase," <i>J. Med. Chem.</i> , 39, 1736-1747 (1996)
		SHIMIZU, K et al., "Prothracarcin, a Novel Antitumor Antibiotic," <i>J. Antibiotics</i> , 35, 972-978 (1982)
		SIMON, R.J. et al., "Peptoids: A Modular Approach to Drug Discovery", <i>Proc. Natl. Acad. Sci. USA</i> , 89:9367-9371 (1992)
		SOTH, M.J. and NOWICK, J.S., "Unnatural oligomers and unnatural oligomer libraries", <i>Curr. Opin. Chem. Biol.</i> , 1:120-129 (1997)
		STAR, W.M., "Light delivery and light dosimetry for photodynamic therapy," <i>Lasers in Medical Science</i> , 5:107-113 (1990)
		SUGGS, J.W. et al., "Synthesis and structure of anthramycin analogs via hydride reduction of dilactams," <i>Tetrahedron Letters</i> , 26, No. 40, 4871-4874 (1985)
		TAKEUCHI, T. et al., "Neothramycins A and B, New Antitumor Antibiotics," <i>J. Antibiotics</i> , 29, 93-96 (1976)
		TEW, K.D. and CLAPPER, M.L., "Glutathione-S-transferase and anti-cancer drug resistance," <i>Mechanism of Drug Resistance in Neoplastic Cells</i> , Woolley, P.V. and Tew, K.D., Eds, Academic Press: Sand Diego, CA 141-159 (1988)
		THURSTON, D.E. and THOMPSON, A.S., "The molecular recognition of DNA," <i>Chem. Brit.</i> , 26, 767-772 (1990)
		THURSTON, D.E. and BOSE, D.S., "Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines," <i>Chem. Rev.</i> , 94:433-465 (1994)
↓		THURSTON, D. E., "Advances in the study of Pyrrolo[2,1-c][1,4] benzodiazepine (PBD) Antitumour Antibiotics", <i>Molecular Aspects of Anticancer Drug-DNA Interaction</i> , Neidle, S. and Waring, M.J., Eds.; Macmillan Press Ltd, 1:54-88 (1993)

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	May 27, 2005
				First Named Inventor	David Thurston
				Group Art Unit	N/A
Examiner Name	N/A				
Sheet	8	of	8	Attorney Docket Number	065435-9048 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--	--

BK		THURSTON, D.E. et al., "Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Journal of Medicinal Chemistry</i> , 42:1951-1964 (1999)
		THURSTON, D.E. et al., "Synthesis of Sequence-selective C8-linked Pyrrolo [2,1-c][1,4] Benzodiazepine DNA Interstrand Cross-linking Agent," <i>J. Org. Chem.</i> , 61:8141-8147 (1996)
		THURSTON, D.E. et al., "Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines (PBDs)," <i>Chemical Communications</i> , 563-565 (1996)
		TSUNAKAWA, M. et al., "Porothramycin, a new antibiotic of the anthramycin group: Production, isolation, structure and biological activity," <i>J. Antibiotics</i> , 41:1366-1373 (1988)
		UMEZAWA, H. et al., Chemical Abstract No. 4427a, "Mazethramycins" <i>Chemical Abstracts</i> , vol. 90, No. 1, 428 (1979)
		UMEZAWA, H. et al., "Mazethramycins," <i>SciFinder Scholar</i> , 2-3 (2002)
		WILSON, S.C. et al., "Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure," <i>Tetrahedron Letters</i> , 36, No. 35, 6333-6336 (1995)
		WILSON, S.C. et al., "Design, Synthesis, and Evaluation of a Novel Sequence-Selective Epoxide-Containing DNA Cross-Linking Agent Based on the Pyrrolo[2,1-c][1,4]benzodiazepine System", <i>J. Med. Chem.</i> 42:4028-4041 (1999)
		ZUCKERMAN, R.N. et al., "Discovery of Nanomolecular Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted) glycine Peptoid Library", <i>J. Med. Chem.</i> , 37:2678-2685 (1994)
↓		<i>Dictionary of Science and Technology</i> , Professor P.M.B. Walker ed. Larousse plc., pp. 63, 457, 523 (1995)

Q:\CLIENT\065435\9048\B0620172.1

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/534,825
Filing Date	October 20, 2005
First named Inventor	David Edwin Thurston
Group Art Unit	1614
Examiner name	Unknown
Attorney Docket Number	065435-9048-US00

## U.S. Patent Documents

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
BK	6,660,856	Wang	12/9/2003

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
BK	EP	1193270	Spirogen Ltd.	4/3/2002		
	GB	2053894	The Green Cross Corporation	2/11/1981		
	WO	88/04659	The Upjohn Company	6/30/1988		
	WO	91/16324	The Upjohn Company	10/31/1991		
	WO	96/23497	Synphar Laboratories, Inc.	8/8/1996		
	WO	97/07097	Auckland Division Cancer Society of New Zealand Inc.	2/27/1997		
	WO	98/11101	Auckland Division Cancer Society of New Zealand Inc.	3/19/1998		
	WO	98/12197	Kyorin Pharmaceuticals Co., Ltd. et al.	3/26/1998	N	Y
	WO	99/29642	The Scripps Research Institute	6/17/1999		
	WO	99/46244	Novo Nordisk A/S et al.	9/16/1999		

Examiner Signature

/Bruck Kifle/ (09/01/2006)

Date

Considered

09/01/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary) Sheet 2 of 2				<b>Complete if Known</b>			
				Application Number		10/534,825	
				Filing Date		October 20, 2005	
				First named Inventor		David Edwin Thurston	
				Group Art Unit		1614	
				Examiner name		Unknown	
				Attorney Docket Number		065435-9048-US00	
U.S. Patent Documents							
FOREIGN PATENT DOCUMENTS							
Examiner Initials		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
BK		WO	00/12508	The University of Portsmouth Higher Education Corp.	3/9/2000		
		WO	00/12509	The University of Portsmouth Higher Education Corp.	3/9/2000		
		WO	00/64864	Cancer Campaign Research Technology Ltd.	11/2/2000		
		WO	2004/043963	Spirogen Ltd.	5/27/2004		
		WO	2005/023814	Spirogen Ltd.	3/17/2005		
		WO	2005/040170	Government of the U.S.A. et al.	5/6/2005		
		WO	2005/085251	Spirogen Ltd.	9/15/2005		


Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.





PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	October 20, 2005
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	1	of	5	Attorney Docket Number	065435-9048-US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK		ADAMS et al., "Molecular modelling of a sequence-specific DNA-binding agent based on the pyrrolo[2,1-c][1,4]benzodiazepines," Pharm. Pharmacol. Commun. (1999) 5:555-560
		BARALDI, P.G. et al., "[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1," Nucleotides and Nucleic Acids (2000) 19(8):1219-1229
		BERGE et al., "Pharmaceutical Salts," J. Pharm. Sci. (1977) 66:1-19
		BORGATTI, M. et al., "Inhibition of NF-kB/DNA interactions and HIV-1 LTR directed transcription by hybrid molecules containing pyrrolo [2,1-c][1,4] benzodiazepine (PBD) and oligopyrrole carriers," Drug Development Research (2003) 60(3):173-185
		BOSE, D.S. et al., "Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8 linked pyrrolobenzodiazepine dimers," J. Chem. Soc. Chem. Commun. (1992) 20:1518-1520
		CHEN, Z. et al., "A novel approach to the synthesis of cytotoxic C2-C3 unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) with conjugated acrylyl C2-substituents," Biorg. Med. Chem. Lett. (2004) 14:1547-1549
		COOPER, N. et al., "Synthesis of novel PBDs as anti-tumour agents," Chem. Commun. (2002) 16:1764-1765
		DE GROOT, FMH et al., "Synthesis and biological evaluation of 2'-carbamate-linked 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin," J. Med. Chem. (2000) 43(16):3093-3102
↓		DE GROOT, FMH et al., "Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin," Biorg. Med. Chem. Lett. (2002) 12(17):2371-2376

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	October 20, 2005
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	2	of	5	Attorney Docket Number	065435-9048-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK		DUBOWCHIK, G.M. et al., "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin," Biorg. Med. Chem. Lett. (1998) 8:3341-3346
		DUBOWCHIK, G.M. et al., "Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), Mitomycin C and Doxorubicin," Biorg. Med. Chem. Lett. (1998) 8:3347-3352
		DUBOWCHIK and WALKER, "Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs," Pharmacology and Therapeutics (1999) 83:67-123
		GARSKY et al., "The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy," J. Med. Chem. (2001) 44:4216-4224
		GREGSON, S.J. et al., "Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo-[2,1-c][1,4]-benzodiazepines," Bioorg. Med. Chem. Lett. (2000) 10(16):1849-1851
		GREGSON, S.J. et al., "Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers," J. Med. Chem. (2004) 1161-1174
		GREGSON, S.J. et al., "Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer," Biorg. Med. Chem. Lett. (2001) 11:2859-2862
		GREGSON, S.J. et al., "Synthesis of the first examples of A-C8/C-C2 amide-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers," Biorg. Med. Chem. Lett. (2003) 13:2277-2280
↓		HAMBURGER, A.W. et al., "Primary bioassay of human tumor stem cells," Science (1977) 197:461-643

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/534,825	
			Filing Date	October 20, 2005	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1614	
			Examiner Name	Unknown	
Sheet	3	of	5	Attorney Docket Number	065435-9048-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK		JAKOBSEN et al., "Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells," J. Med. Chem. (2001) 44:4696-4703
		KAMAL et al., "Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers" Biorg. Med. Chem. Lett. (2003) 13(22):3955-3958
		KAMAL, et al., "Synthesis of pyrrolo[2,1-c][1,4]benzodiazepines via reductive cyclization of w-azido carbonyl compounds by TMSI: an efficient preparation of antibiotic DC-81 and its dimers," Biorg. Med. Chem. Lett. (2000) 10:2311-2313
		KANEKO, T. et al., "Bicyclic and tricyclic analogues of anthramycin," J. Med. Chem. (1985) 28:388-392
		KANG, G.-D. et al., "Synthesis of a novel C2-aryl substituted 1,2-unsaturated pyrrolobenzodiazepine," Chem. Commun. (2003) 1688-1689
		KUMAR, R. et al., "Synthesis and antitumor cytotoxicity evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine imidazole containing polyamide conjugates," Oncology Research (2003) 13(4):221-223
		KUMAR, R. et al., "Design and synthesis of novel pyrrolo[2,1-c][1,4]benzodiazepine - imidazole containing polyamide conjugates," Heterocyclic Communications (2002) 81(1):19-26
		KUMAR, R. et al., "Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo [2,1][1,4]benzodiazepine-glycosylated pyrrole and imidazole polyamide conjugates," Org. Biomol. Chem. (2003) 1(19):3327-3342
↓		LANGLOIS, N. et al., "Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin," J. Med. Chem. (2001) 44:3754-3757

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	October 20, 2005
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	4	of	5	Attorney Docket Number	065435-9048-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK		LIPSHUTZ, B.H. et al., "Pd(II)_Catalyzed Acetal/Ehtal Hydrolysis/Exchange Reactions," Tetrahedron Lett. (1985) 26(6):705-708
		MHAKA et al., "A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer," Biorg. Med. Chem. Lett. (2002) 12(17:2459-2461
		MISCHIATI, C. et al., "Binding of hybrid molecules containing pyrrolo [2,1-c][1,4]benzodiazepine (PBD) and oligopyrrole carriers to the human immunodeficiency type 1 virus TAR-RNA," Biochem. Pharmacol. (2004) 67(3):401-410
		MORI, M. et al., "Total syntheses of prothracarcin and tomaymycin by use of palladium catalyzed carbonylation," Tetrahedron (1986) 42(14):3793-3806
		MOUNTZOURIS, J.A. et al., "Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-Tomamycin adduct," J. Med. Chem. (1994) 37:3132-3140
		NICULESCU-DUVAZ, D. et al., "Self-immolative nitrogen mustard prodrugs for suicide gene therapy," J. Med. Chem. (1998) 41(26):5297-5309
		REDDY et al., "Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyamide conjugates and 2,2'-PBD dimers," Anti-Cancer Drug Design (2000) 15(3):225-228
		SPELLIE, M. et al., "Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents," Br. J. Cancer (1994) 70:48-53
↓		SPELLIE, M. et al., "Sequence selective recognition of duplex DNA through covalent interstrand cross-linking," Biochem. (2003) 42:8232-8239

Examiner Signature	/Bruck Kifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/534,825
				Filing Date	October 20, 2005
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1614
				Examiner Name	Unknown
Sheet	5	of	5	Attorney Docket Number	065435-9048-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
BK		THURSTON, D.E., "Nucleic acid targeting: therapeutic strategies for the 21st century," Brit. J. Cancer (1999) 80(1):65-85
		TIBERGHIE, A.C. et al., "Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)," Biorg. Med. Chem. Lett. (2004) 14:5041-5044
		WELLS, G. et al., "Pyrrolobenzodiazepine-polyamide libraries: synthesis and DNA binding selectivity," Proc. Am. Assoc. Canc. Res. (2003) 44:85-86, #452
		WERMUTH et al., "Molecular Variations Based on Isosteric Replacements," The Practice of Medicinal Chemistry, Chapter 13 (1996) 203-237
		WILLIAMS, M.A. et al., "Synthesis of conformationally constrained DTPA analogues. Incorporation of the ethylenediamine units as aminopyrrolidines," J. Org. Chem. (1994) 59(13):3616-3625

Examiner Signature	/Bruck Rifle/ (09/01/2006)	Date Considered	09/01/2006
-----------------------	----------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.